Publication Name	World Journal of Gastroenterology
Manuscript ID	36922
Country	Italy

Received	2017-10-29 02:11
Peer-Review Started	2017-10-29 05:48
To Make the First Decision	2017-11-22 01:03
Return for Revision	2017-11-27 08:59
Revised	2017-11-27 09:25
Second Decision	2017-12-04 09:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-12-04 19:48
Articles in Press	2017-12-04 19:48
Publication Fee Transferred
Edit the Manuscript by Language Editor	2017-12-11 21:36
Typeset the Manuscript	2017-12-13 09:37
Publish the Manuscript Online	2017-12-20 02:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities
Manuscript Source	Invited Manuscript
All Author List	Giuseppe Lippi and Fabian Sanchis-Gomar
ORCID	Author(s) ORCID Number Giuseppe Lippi http://orcid.org/0000-0001-9523-9054 Fabian Sanchis-Gomar http://orcid.org/0000-0003-0424-4208
Funding Agency and Grant Number
Corresponding Author	Giuseppe Lippi, MD, Professor, Section of Clinical Biochemistry, University of Verona, Piazzale L.A. Scuro, 10, Verona 37100, Italy. giuseppe.lippi@univr.it
Key Words	Intestinal bowel disease; Chron’s disease; Ulcerative colitis; Procalcitonin
Core Tip	According to current evidence, the clinical significance of measuring procalcitonin for diagnosing intestinal bowel disease (IBD) or monitoring disease activity remains elusive. Nevertheless, literature data suggests that supranormal procalcitonin concentrations may reflect the presence of a number of infective complications in IBD, including bacterial enterocolitis, bacterial gastroenteritis, intraabdominal abscess, postsurgical infection and sepsis. Rather than for assessing disease activity, the measurement of this biomarker may hence retain clinical significance for predicting or timely diagnosing of many IBD-associated infections and complications.
Publish Date	2017-12-20 02:49
Citation	Lippi G, Sanchis-Gomar F. Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. World J Gastroenterol 2017; 23(47): 8283-8290
URL	http://www.wjgnet.com/1007-9327/full/v23/i47/8283.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i47.8283

Full Article (PDF)	WJG-23-8283.pdf
Full Article (Word)	WJG-23-8283.doc
Manuscript File	36922-Review.doc
Answering Reviewers	36922-Answering reviewers.pdf
Audio Core Tip	36922-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	36922-Conflict-of-interest statement.pdf
Copyright License Agreement	36922-Copyright license agreement.pdf
Peer-review Report	36922-Peer-review(s).pdf
Scientific Editor Work List	36922-Scientific editor work list.pdf